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ABSTRACT
Renal targets of autoimmunity in human lupus nephritis (LN) are unknown. We sought to identify autoanti-
bodies and glomerular target antigens in renal biopsy samples from patients with LN and determine whether
the same autoantibodies can be detected in circulation. Glomeruli weremicrodissected from biopsy samples
of 20 patients with LN and characterized by proteomic techniques. Serum samples from large cohorts of
patients with systemic lupus erythematosus (SLE) with and without LN and other glomerulonephritides were
tested. Glomerular IgGs recognized 11 podocyte antigens, with reactivity varying by LNpathology. Notably,
IgG2 autoantibodies against a-enolase and annexin AI were detected in 11 and 10 of the biopsy samples,
respectively, and predominatedover other autoantibodies. Immunohistochemistry revealed colocalizationof
a-enolase or annexin AI with IgG2 in glomeruli. High levels of serum anti–a-enolase (.15 mg/L) IgG2 and/or
anti-annexin AI (.2.7 mg/L) IgG2 were detected in most patients with LN but not patients with other glo-
merulonephritides, and they identiﬁed two cohorts: patients with high anti–a-enolase/low anti-annexin AI
IgG2 and patients with low anti–a-enolase/high anti-annexin AI IgG2. Serum levels of both autoantibodies
decreased signiﬁcantly after 12months of therapy for LN. Anti–a-enolase IgG2 recognized speciﬁc epitopes
ofa-enolase and did not cross-react with dsDNA. Furthermore, nephritogenicmonoclonal IgG2 (cloneH147)
derived from lupus-prone MRL-lpr/lpr mice recognized human a-enolase, suggesting homology between
animal models and human LN. These data show a multiantibody composition in LN, where IgG2 autoanti-
bodies against a-enolase and annexin AI predominate in the glomerulus and can be detected in serum.
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Lupus nephritis (LN) is the most serious organ manifestation of
systemic lupus erythematosus (SLE).1 It occurs in a relevant pro-
portion of SLE patients and if not timely recognized and treated,
may lead to renal failure and death. There is a general consensus
that LN ismediated by antibody deposition in glomerular tuft,2–5
but the mechanisms leading to the formation of immune depos-
its and the development of renal lesions are not completely
clariﬁed. The glomerular targets of pathogenic antibodies, in
particular, are not well deﬁned. Consequently, no surrogate bio-
marker is available that could allow early identiﬁcation of candi-
date patients to LN and/or drive the therapeutic approach.
Several theories have been developed over the years.6–12
They consider a pre-eminent role of circulating anti–double
stranded DNA (dsDNA) antibodies that they can interact, for
mimicry, with glomerular antigens expressed at the cell
surface of podocytes and mesangial cells7,13–15 or in the glo-
merular basement membrane.12,16–20 Chromatin and nucleo-
somes deriving from ineffective fragmentation may interact
with negatively charged constituents of the basement mem-
brane7,16 and become the planted antigen for anti-dsDNA
(and autoantibodies of other speciﬁcities).6,7,9,16
Other potentially nephritogenic antibodies different from
anti-dsDNA have been proposed10,11,21–26; overall, it has been
estimated that anti-DNA deposition in LN accounts for not
more than 10%–20% of eluted IgG overall,27 implying that
IgG not recognizing DNA represents the vast majority of anti-
bodies in glomeruli. Renal targets of autoimmunity in human
LN are, however, unknown.
An in vivo approach based on antibody microelution from
glomeruli dissected from renal biopsies of LN patients and their
characterizationwith proteomics seems potentially conclusive to
elucidate main features of human LN. Studies published so far
on direct analysis of antibodies eluted from glomeruli in patients
with LN have been done only on autoptic samples of kidney
tissue and focused only on renal targets of eluted anti-
dsDNA.27,28 Ultraprecise techniques of dissection, such as laser
capture, allow repetitive analysis of minute amounts of renal
tissue and can be used routinely in vivo,29 which has already
been done in membranous nephropathy.30,31
The aim of the present study was to evaluate the target
antigens of antibodies eluted from glomeruli of LN patients to
characterize their isotype and determine their serum levels in
different cohorts of patients with SLE (with and without
nephritis). Antigen targets in murine models of LN were
characterized as well.
RESULTS
Anti-Podocyte Antibodies in Glomerular Eluates and
Serum
For the analysis of glomerular eluates, we used renal biopsies
obtained from20SLEpatientswithproteinuriawhounderwenta
renal biopsy for diagnostic purposes (Table 1). Glomeruli were
dissected from frozen kidneys by laser capture, and eluted Igs
were analyzed by Western blot using podocyte extracts as ﬁxed
Table 1. Clinical data and pathology characteristics relative to 20 patients with SLE who underwent a renal biopsy at the time
of enrolment and had their renal tissue processed with laser capture for antibody characterization
Patient Sex
Age
(yr)
Biopsy
Year
LN Class
SCreat
(mg/dl)
UProt
(g/24 h)
C3
(mg/dl)
C4
(mg/dl)
ANA
Anti-
DNA
Steroid Cycloph Cyclosp MMF Plaquenil
1 M 16 2010 IV 0.5 2.2 103 16 Pos Pos Yes No No No No
2 M 22 2005 III 0.6 0.9 44 8 Pos Pos Yes No No No No
3 M 19 2010 V 2.4 0.9 78 12 Pos Pos Yes No No No No
4 W 18 2009 IV 0.4 1.4 65 10 Pos Pos Yes No No No No
5 W 25 2005 V 0.5 1.1 47 19 Pos Pos Yes No No No Yes
6 W 28 2005 nd 2.1 0.2 102 20 Pos Pos Yes No Yes Yes No
7 W 20 2007 II 0.4 0.6 60 10 Pos Pos Yes No No No No
8 W 17 2009 IV and V 0.7 0.8 47 ,3 Pos Pos Yes No No No Yes
9 W 25 2004 IV 0.9 1.8 5 20 Pos Pos Yes No No No Yes
10 W 43 2010 IV 0.8 1.4 53 6 Pos Pos Yes No No Yes Yes
11 W 44 2010 IV and V 0.7 0.9 46 4.8 Pos Pos Yes No No Yes Yes
12 W 53 2010 III 0.6 2.8 141 18 Pos Pos Yes No No Yes No
13 W 34 2009 IV 0.8 2.8 53 11.5 Pos Pos Yes Yes No No Yes
14 W 40 2009 III 0.5 1.4 71 10.7 Pos Pos Yes No No Yes Yes
15 W 25 2009 V 0.6 3.3 63 12.1 Pos Pos Yes No No Yes Yes
16 W 38 2009 IV 0.6 4.5 41 4.1 Pos Pos Yes Yes No No Yes
17 W 50 2009 IV 1.0 1.9 75 10 Pos Pos Yes No No Yes Yes
18 W 35 2010 IV 0.7 2.1 47 2.5 Pos Pos Yes Yes No No Yes
19 W 31 2011 IV 0.8 5.7 23 2.4 Pos Pos Yes No No Yes No
20 W 27 2011 nd 1.0 1.0 50 5 Pos Pos Yes No No No No
SCreat, serum creatinine; UProt, proteinuria; ANA, antinuclear antibody; Cycloph, cyclophosphimide; Cyclosp, cyclosporine; MMF, mycophenolate mofetil; M,
man; Pos, positive; W, woman; nd, not determined.
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antigens. An example showing laser capture
efﬁciency and precision is shown in Supple-
mental Figure 1.
Pooled samples from different patho-
logic classes of LN (classes III–V) were ﬁrst
analyzed; a separate set of analysis of elu-
ates from each renal biopsy was then car-
ried out with dot blot after antigens had
been characterized (see below for informa-
tion on speciﬁc antibodies). As shown in
Figure 1, glomerular IgGs recognized 11
proteins (Figure 1, A–D) that were charac-
terized by matrix-assisted laser desorption
ionization (MALDI)–mass spectrometry
(MS) and liquid chromatography (LC)-
MS. The predicted sequence for each rec-
ognized protein is reported in Table 2. The
presence of speciﬁc autoantibodies in glo-
merular eluates versus this panel of pro-
teins varied in different patients according
to the pathology classes of LN, with only
anti–a-enolase and anti-annexin AI being
present in all eluates (Table 3). Five auto-
antibodies were detected in at least two
pathology classes (anti-tubulin, anti–
gluthatione synthetase, anti–heat shock
cognate 71 kD, anti–Xaao dipeptidase,
and anti–lactate dehydrogenase), and four
autoantibodies were found in just one class
(i.e., anti-ezirin/moesin, anti-transketolase,
anti-vimentin, and heat shock protein/
perodoxiiredoxin).
Serum IgGs from the same LN patients
recognized most of the antigens above
(Figure 1, E and F) with the following ex-
ceptions: anti–Xaa Pro dipeptidase (spot
D), transketolase (spot F), and anti-heat
shock protein perodoxiiredoxin 6 (spot J)
were not detected in serum, whereas anti-
cytosolic dipeptidase antibodies were
found in serum but not glomeruli. All
other components were conﬁrmed in both.
Based on the presence of anti–a-enolase
and anti-annexin AI antibodies in all the
LN pathology classes and serum, focused
studies addressed isotypes of these anti-
bodies in glomeruli and serum, single biopsy
expression, antigen–antibody colocalization,
and speciﬁcity.
Renal Anti–a-Enolase/Anti-Annexin
AI Antibodies: Isotype, Glomerular
Expression, and Colocalization
Isotype analysis of anti–a-enolase in glomerular eluates
showed IgG2 and a minimal amount of IgG1 (Figure 2A);
anti–a-enolase IgG3 and IgG4 were negative. Overall, speciﬁc
anti–a-enolase IgG2 was detected in 11 of 20 renal biopsy
samples processed with microdissection (Figure 2A).
Figure 1. Characterization of autoantibodies eluted from glomeruli of patients with LN
and in corresponding serum. (A and E) Representative two-dimensional electrophoresis
of podocyte cell extracts stained by colloidal Coomassie.57 The same cell extract was
incubated with antibodies eluted from microdissected glomeruli obtained from pa-
tients with different classes of LN: (B) class III, (C) class IV, and (D) class V. Microeluted
antibodies from normal kidneys did not react with any protein. Several spots were
recognized by LN eluates and identiﬁed as 11 different proteins (A–K). One was
characterized by LC-MS (spot I; a-enolase), and the remaining spots were character-
ized by MALDI-MS (Table 2). Their identity as predicted by MS is reported in Table 2.
The same podocyte cell extracts separated by two-dimensional electrophoresis were
incubated with normal sera (not shown) and (F) pooled LN sera (classes III–V) and then
developed with anti-IgG (total) antibodies. Several proteins were detected, and most
corresponded to proteins recognized in glomerular eluates (A–C and G–I); three
proteins were recognized only in serum or a few glomerular eluates (K and L). All spots
were characterized by LC-MS or MALDI-MS as above (Table 2, Supplemental Table 1).
Their identity is reported in Table 2.
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Isotype analysis of glomerular anti-annexin AI showed IgG2
as a unique category (Figure 2B). Analysis in every separate renal
biopsy sample showed the presence of anti-annexinAI IgG2 in 10
of 20 samples (Figure 2B); in other renal samples, the expression
was scanty. In six cases, a double positivity for anti–a-enolase and
anti-annexin AI IgG2 was observed. Multiple positivity for sep-
arate renal biopsy samples was analyzed with cluster analysis
(heat map), and results are shown as intensity variation from
black (maximum) to white (minimum) in Figure 2C. Other
than results on anti–a-enolase and anti-annexin AI antibodies,
in Figure 2C, it is also reported, for comparison, positivity of
single biopsy for antibodies versus implanted
antigensanti-C1q, anti-DNA,andanti-histones
H2A, H3, and H4, which are typical ﬁnd-
ings in LN. With this type of approach, the
intensity relative to all autoantibodies can be
evaluated simultaneously in all biopsies. The
results conﬁrmed predominance of antibod-
ies versus endogenous glomerular antigens
followed by anti-DNA and anti-C1q.
Other experiments showed colocaliza-
tion ofa-enolase and annexin AIwith IgG2
in glomeruli of patients with LN. Figure 3
shows two examples of patients with LN
classes III and V presenting with diffuse
a-enolase expression and widespread
IgG2 deposition. Vast areas of colocaliza-
tion with IgG2 could be shown for both
a-enolase and annexin AI that were ob-
served also after DNase/RNase treatment
(Supplemental Figure 2), implying that
the target antigen is not a planted DNA or
nucleosome structure.
Serum Anti–a-Enolase/Anti-Annexin
AI: Isotype, Circulating Levels, and
Correlations
The isotype of serum anti–a-enolase and
anti-annexin AI was less selective than in
glomeruli; even IgG2 was the major com-
ponent. Minor amounts of anti-annexin AI
IgG1 and IgG3 (Figures 4A and 5A) were
observed.
Circulating levels of anti–a-enolase
IgG2 (Figure 4, B and C) and anti-annexin
AI IgG2 (Figure 5B) were determined with
dot blot analysis and ELISA in several SLE
and non-SLE patients; antibodies of the
other isotypes were evaluated as well (Fig-
ure 4B, Supplemental Figure 4). The fol-
lowing patient categories were considered
(Table 4, Supplemental Table 1): 104 LN
patients recruited at the time of renal bi-
opsy, 112 SLE patients without LN, 50 pa-
tients with rheumatoid arthritis, and 278
patients with isolated glomerulonephrites.
Serum levels of anti–a-enolase IgG2were higher than the 95°
limit of normal levels in 82% of the LN patients (Figure 4, B and
C). Anti–a-enolase IgG1 and IgG3 serum levels were undetect-
able in all patient categories (Figure 4B); anti–a-enolase IgG4
was negative in LNand SLEpatients but high,which is known, in
patients with membranous nephropathy31 (Supplemental Fig-
ure 4B). Fewer SLE patients and no patients with rheumatoid
arthritis or primary GN presented anti–a-enolase IgG2 levels
exceeding normal values (Figure 4C). The median of serum
levels of anti–a-enolase IgG2 was statistically higher in LN
Table 2. MALDI-MS/LC-MS spectra analyses of protein spots (A–L) from two-
dimensional electrophoresis
Spot Gene Name Protein Name Technique Score Coverage
A TBA1B Tubulin a-1B chain MALDI-MS 1011 48.8
TBB5 Tubulin b-chain 2 961 42.6
B GSHB Glutathione synthetase MALDI-MS 712 32.7
C HSP7C Heat shock cognate 71 kD protein MALDI-MS 1087 36.1
D PEPD Xaa-Pro dipeptidase MALDI-MS 208 13.4
E EZRI Ezrin MALDI-MS 679 23.7
MOES Moesin 1465 45.8
F TKT Transketolase MALDI-MS 713 27.4
G ANXAI Annexin AI MALDI-MS 1575 74.3
H LDHA L-lactate dehydrogenase A chain MALDI-MS 507 32.8
K VIM Vimentin MALDI-MS 512.3 57.5
J HSPB1 Heat shock protein b-1 MALDI-MS 521 41.5
PRDX6 Peroxiredoxin-6 MALDI-MS 838 63.8
I.1 ENOA a-Enolase LC-MS 94.3 13.9
I.2 ENOA a-Enolase LC-MS 178.4 18.2
I.3 ENOA a-Enolase LC-MS 194.3 18.8
I.4 ENOA a-Enolase LC-MS 99.2 14.2
L CNDP2 Cytosolic nonspeciﬁc dipeptidase MALDI-MS 279 19.4
Proteins identiﬁed by two-dimensional electrophoresis from podocyte extracts were characterized by
MALDI-MS in most cases (spots A–H and J–L) and LC-MS in one case (spot I). Structure prediction
features (score and coverage) are reported.
Table 3. Positivity of antibodies versus different podocyte antigens in serum
and glomerular eluates of patients with different classes of LN as evaluated by
two-dimensional electrophoresis/Western blot
Spot Protein Name Serum GN Class III GN Class IV GN Class V
A Tubulin-a/b + + + 2
B Glutathione synthetase + + + 2
C Heat shock cognate 71 kD + + + 2
D Xaa Pro dipeptidase 2 + + 2
E Ezirin + 2 2 2
Moesin
F Transketolase 2 2 + 2
G Annexin AI + + + +
H L-lactate dehydrogenase + + + 2
K Vimentin + 2 2 +
I a-Enolase + + + +
L Cytosolic nonspeciﬁc dipeptidase + 2 2 2
J Heat shock protein b-1 2 2 + 2
Perodoxiredoxin-6
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(45.37 mg/L) versus SLE (17.44 mg/L) patients and much more
versus the other patient cohorts (Table 5). The area under the
receiver operating characterisitc curves for anti–a-enolase IgG2
was signiﬁcantly greater in LN patients compared with SLE pa-
tients, rheumatoid arthritis patients, and patients with other
nephropathies (Figure 4, E–L). The results relative to anti–a-enolase
IgG2 were conﬁrmed by a self-made ELISA (Supplemental
Figure 3). Some of the LN patients who had been evaluated
at the beginning of disease were re-evaluated after 6 and 12
months, duringwhich time they had received speciﬁc treatments
Figure 2. Glomerular a-enolase and annexin AI: isotypes and levels in single biopsies. The following studies were done to better
characterized (A) anti–a-enolase and (B) anti-annexin AI antibodies: study 1, deﬁnition of isotype with dot blot analysis; study 2, single
biopsy analysis; and study 3, competition experiment using the same glomerular eluates as above and increasing amounts of
a-enolase/annexin AI from 5 to 15 ng to saturate antibodies. Results show complete inhibition and conﬁrm the presence of anti–
a-enolase/anti-annexin AI IgG2 in glomerular eluates. (C) Hierarchical cluster analysis heat map for a single antibody in each renal
biopsy; antibody intensities (black, high; gray, medium; white, low) are reported in lines and refer to single patient biopsies that are
reported at the bottom of the ﬁgure. Results are given for 20 LN patients of our study cohort and four normal kidneys.
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(steroids and cyclophosphamide, mycophenolate mofetil, or
tacrolimus): a signiﬁcant decrease of anti–a-enolase IgG2 was
reached at T12 (Figure 4D).
Circulating anti-annexin AI IgG2 levels were determined
with a self-made ELISA in the same patient cohorts. Results
reported in Figure 5B and Table 5 indicate median levels one
order of magnitude lower than anti–a-enolase IgG2 levels.
Also, in this case, LN patients had higher levels than SLE pa-
tients (median of 4.250 versus 2.249 mg/L), and the difference
was much more evident in other patient cohorts (Table 5).
Twelve months after the start of therapy, LN patients
presented a signiﬁcant decrease of anti-annexin AI levels
(2.251 mg/L).
Patients with double positivity for circulating anti–a-enolase
and anti-annexin AI IgG2 were identiﬁed with heat map anal-
ysis (Figure 5D). A clear demarcation was observed among
patients with LN regarding serum levels of the two antibodies,
with one population presenting high anti–a-enolase in con-
comitance with low anti-annexin AI IgG2 (red indicates high
levels and green indicates low levels in Figure 5D) and vice
versa. Intermediate levels (Figure 5D, black) could be detected
in a few patients. This result identiﬁes two distinct patient
cohorts with potentially different clinical characteristics and
possibly, different mechanisms. Before deﬁnitive clinical con-
siderations can be done, we need to have an overall picture of
all antibodies present in glomeruli and serum of patients with
LN, which also includes implanted antigens (G.M. Ghiggeri,
unpublished data).
Anti–a-Enolase Antibodies Antigen Binding Epitopes
and Speciﬁcity
To better characterize anti–a-enolase antibodies, we analyzed
the epitopes recognized by these antibodies: a-enolase cyan-
ogen bromide (CNBr) digests were probed with IgG2 puriﬁed
from glomeruli and serum of patients with LN and SLE or
IgG4 eluted from glomeruli of patients with membranous
nephropathy (a category of patients that has been recently
recognized as having high levels of anti–a-enolase IgG4 in
glomeruli and serum (Figure 6, A–C).30,31 IgG2 and IgG4
recognized different peptides derived from CNBr fragmenta-
tion with 1.3 kD (ILPVGAANFREAM) and 6.8 kD
(DGTENKSKFGANAILGVSLAVCKAGAVEKGVPLYRHIA-
DLAGNSEVILPVPAFNVINGGSHAGNKLAM), respectively
(arrows in Figure 6A). Epitope mapping for the IgG2 and
IgG4 recognition sites in the a-enolase model is reported in
Figure 6A.
A set of experiments was done to exclude interaction of
anti-DNA antibodies with a-enolase. Anti-dsDNA antibodies
were isolated from both serum and renal biopsies of several
LN patients.32 On repeated experiments, puriﬁed anti-
dsDNA recognized several histones (only H1 and H2b were
negative) but did not recognize a-enolase, even when the
amount of the protein in the dot blot assay was signiﬁcantly
increased (Figure 6, D–F). At variance, in the same dot blot
essay using the same a-enolase amount, anti–a-enolase anti-
bodies recognized the protein at low concentration (5 mg).
Taken together with the results of colocalization after DNase/
RNase treatment (Supplemental Figure 2), these ﬁndings ex-
clude an interaction between anti–a-enolase/anti-annexin AI
IgG2 with DNA and an interaction of anti-DNA antibodies
with a-enolase.
Lupus-Prone Mice
LN is reproduced in mice by infusion of monoclonal anti-
DNA IgG2 produced by cells derived from lupus-proneMRL-
lpr/lpr mice.12 The prototype produced by clone H147 (an
IgG2 encoded by 7183/81X VH gene)33 induces the forma-
tion of glomerular or tubular basement membrane, mesangial
immune deposits, and proliferative GN after passive trans-
fer to normal mice.12 The target antigen of these antibodies
was recognized as a protein of 46 kD, which is the same
molecular mass of a-enolase in the work by D’Andrea and
colleagues,12 but it has not been characterized until now.
We attempted to ﬁll this gap by characterizing the target
Figure 3. Colocalization of IgG2 with a-enolase and annexin AI.
In this series, the colocalization of each endogenous antigen
(a-enolase and annexin AI) with IgG2 within renal biopsy samples
is reported. For each antigen/antibody, confocal images of two
renal biopsy specimens are shown relative to patients with LN
classes III and V. Double immunoﬂuorescence staining was
evaluated for each antigen (red) and IgG2 (green). Merged im-
ages are reported in yellow. RNase treatment of the same renal
tissue did not modify colocalization of anti–a-enolase and IgG2
(Supplemental Figure 2). Magniﬁcation of this ﬁgure is in Sup-
plemental Material. Original magniﬁcation, 3630. Scale bars, 20
mm.
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protein of the mouse IgG2 above (a gift from M.M.) and
found that these antibodies at various dilutions recognize
a-enolase at dot blot (Figure 7A). This ﬁnding shows
important similarities in LN in humans and mice and
strongly supports the implication of anti–a-enolase anti-
bodies in murine LN.
Figure 4. Serum anti–a-enolase isotype and levels. (A) Characterization of serum anti–a-enolase isotype with dot blot analysis. (B) The
same technique was used to determine serum anti–a-enolase IgG1-IgG2-IgG3-IgG4 in patients with lupus erythematosus with (LN;
n=104) and without (SLE; n=112) nephritis and several other control populations, including rheumatoid arthritis (RA; n=50), mem-
branous nephropathy (MN; n=186), IgA nephropathy (IgA; n=60), FSGS (n=32), and normal controls (n=135). (C) Levels of anti–
a-enolase IgG2 were very high in most patients with LN, whereas (D) other isotypes (IgG1, IgG3, and IgG4) were undetectable. (D)
Patients with LN were evaluated at T0, and after 6 and 12 months of therapy, results showed a decrease of antibody levels after
therapy. Dot blot analysis using recombinant a-enolase linked to nitrocellulose as antigen (Supplemental Figure 4); results (evaluated as
the signal intensity of chemiluminescence detected by VersaDoc and computed with QuantyOne software; Bio-Rad) were transformed
(milligrams per liter) using a standard curve of chemioluminescent IgG2. The horizontal line is set at the 95th percentile of levels titrated
in normal controls. Receiver operating characterisitc curves for anti–a-enolase IgG2 were signiﬁcantly greater in LN patients compared
with other patient series: (E) normal subjects, (F) SLE, (G) RA, and (H–J) other nephropathies.
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Infusion of Anti–a-Enolase Antibodies in Mice
For anti–a-enolase antibodies, 22 BALB/c mice were injected
intraperitoneally with hybridomas producing IgG anti–
a-enolase antibodies or IgM anti-dsDNA antibodies as a nega-
tive control. Proteinuria (100–300mg%)was detected in 25%of
injected animals after 10 days from injection (Figure 7B); pro-
teinuria in control mice was constantly less than 10 mg%. Renal
histology showed diffuse glomerular proliferative lesions in 5 of
22 mice injected with anti–a-enolase monoclonals (Figure
7D). In two mice, proliferative lesions coexisted with basement
membrane thickening, and in one case, proliferative lesions co-
existedwith FSGS. Few tubular inﬁltrates were observed. Inmice
infused with anti–a-enolase antibodies, mesangial deposits of
nonmuscle myosin were seen in glomeruli and small vessels
(where nonmuscle myosin is physiologic), whereas no mesangial
staining could be found in mice injected with anti-DNA IgM
(Figure 7E). Mice injected with monoclonal IgM anti-DNA de-
veloped only focal glomerular inﬁltrates.
Four of six SCID mice similarly injected with the same
hybridomas developed proliferative GN with crescents and
tubulointerstitial lesions (Figure 7F). Proteinuria was, in these
cases, minimal, which is in agreement with the basic ﬁnding of
cell proliferationwithin Bowman cells and interstitial inﬁltration.
DISCUSSION
This study is the ﬁrst study attempting to deﬁne the identity of
glomerular targets of autoantibodies in humanLN in vivo. New
technologies based on laser capture microdissection and pro-
teomics made this evolution possible. The crucial point of the
programwas to use human biopsies from a relevant number of
patients with LN and cross-match the presence of microeluted
antibodies versus renal and implanted antigens with the ho-
molog sera. The strength of our study is the in vivo approach
based on renal biopsies and the reproducibility of results. The
novelty of our ﬁndings is the characterization of an autoanti-
body panel in kidneys of human LN, which deﬁnes IgG2 as a
major isotype. The potential beneﬁt is linked to the deﬁnition
of mechanisms and the characterization of speciﬁc surrogate
biomarkers of LN.
The characterization in vivo of speciﬁc autoantibodies ver-
sus podocyte antigens in glomeruli of LN patients was a main
objective. Considering concomitance of autoantibodies in glo-
meruli and serum as a criterion to deﬁne importance, anti–
a-enolase and anti-annexin AI emerged among a list of 11
proteins and were further evaluated. Actually, antibodies ver-
sus these two proteins were detected in more than 50% of
Figure 4. Continued.
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Figure 5. Serum anti-annexin AI isotype and levels. (A) Characterization of serum anti-annexin AI isotype with dot blot analysis. (B) Serum
levels of anti-annexin AI IgG2 were determined with a self-made ELISA in the same cohort of patients described in Figure 4; the
technique is described in Supplemental Material. (C) Patients with LN were evaluated at T0, and after 6 and 12 months of therapy,
results showed a decrease of antibody levels after therapy. (D) Double positivity for both anti–a-enolase and anti-annexin AI IgG2 in the
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biopsies that were relevant, because other autoantibodies,
including antibodies versus implanted antigens, were less ex-
pressed. It is also worth noting that we could exclude any in-
teraction of a-enolase with anti-DNA antibodies puriﬁed
from serum and renal biopsies. Finally, characterization of a
single autoantibody in glomeruli indicated IgG2 as the unique
deposited component; this crucial ﬁnding inﬂuenced the
search for circulating biomarkers, posing the basis for the
deﬁnition of speciﬁc antibodies. The implication of anti–
a-enolase IgG2 has been, in particular, addressed on the basis
of homology with experimental models of LN and will be
discussed below. Anti-annexin AI antibodies in SLE are not
new,34–36 because they have been proposed as markers of dis-
coid lupus erythematosus,34 and more generally, high serum
levels have been detected in small series of patients with sys-
temic autoimmune diseases,14 particularly anti-phospholipid
syndrome.35 The demonstration of speciﬁc anti-annexin AI
IgG2 in glomeruli emerges as a major ﬁnding of this work and
strengthens their implication in LN. Other than anti–
a-enolase and anti-annexin AI, the panel of antibody versus
podocyte antigens included proteins of the cytoskeleton, such
as vimentin and ezirin/moesin, or cytosol enzymes, such as
glutathione synthetase, lactate dehydrogenase, and transketo-
lase. It is of note that other antibodies previously proposed as
markers of disease, such as anti–a-actinin and antilaminin
antibodies,37–39 could not be detected in glomeruli with our
approach. We cannot exclude that sensitivity problems of our
methods caused the failure to detect these antibodies in
glomeruli of LN patients, because a-actinin and laminin are
expressed by cell lysates at very low levels. However, both anti–
a-actinin and antilaminin antibodies have been never be
documented in the kidney of human LN and data of the lit-
erature indicate that both proteins cross-react with anti-DNA
antibodies.38,40 Therefore, additional studies must address the
role of anti–a-actinin and antilaminin antibodies before con-
cluding on this aspect.
A special focus of our study was a-enolase, because its se-
rum levels are very high (in the range of 40–50 mg/L, with
peaks up to 300 mg). Indeed, anti–a-enolase IgG has been
detected in clinical conditions involving the kidney other
than LN, and with the methodology limitations that character-
ized the preproteomics era, it has been generically associated
with different autoimmune and inﬂammatory patholo-
gies.25,26,41–43 Previous works on anti–a-enolase did not
characterize the isotype of antibodies and reported variable
results, overall suggesting a limited speciﬁcity for various clin-
ical conditions, such as SLE (data on LN not reported), mixed
cryoglobulinemia, systemic sclerosis, and ANCA vasculitis.41
Recently, we eluted anti–a-enolase IgG4 from glomeruli of
patients with primary membranous nephropathy31 and detec-
ted speciﬁc antibodies of the same isotype in their serum.44 It
is noteworthy that IgG2 was constantly absent in both glomer-
ular eluates and circulating enolase antibodies of patients with
membranous nephropathy.31,44 In our hand, patients with
rheumatoid arthritis and other GNs were frankly negative
for circulating anti–a-enolase IgG2.
It is of interest that anti–a-enolase IgG2 and IgG4 (puriﬁed
from patients with membranous nephropathy) recognize dif-
ferent fragments deriving from the a-enolase CNBr digestion,
suggesting that different parts of the protein become immu-
nogenic in different clinical conditions. This basic ﬁnding
opens up consideration of different mechanisms with deter-
minant structural basis for autoantibody formation.
Analysis of target renal antigens in spontaneous animal
models of LN strengthens the results from the human study.
Actually, there are many factors inﬂuencing the development
(variable genetics and environment) or progression (diet,
lifestyle, sensitivity to therapies, etc.) of LN in humans that are
controlled in animal models, suggesting that any comparison
should be considered with circumspection. However, data on
a-enolase in lupus-prone mice and anti–a-enolase in BALB/c
mice go in the direction of a direct mechanism linked to anti–
a-enolase and anti-annexin AI antibodies. In fact, it is shown
different cohorts of patients with LN was analyzed with hierarchical cluster analysis. Results are presented as a heat map, in which color
intensity (from red [high] to black [medium] to green [low]) indicates levels in separate patients. Two clusters could beobserved: one cluster
had high annexin AI and low anti–a-enolase IgG2 (bottom group; red), and one cluster had low annexin AI and high anti–a-enolase IgG2
(top group; green).
Table 4. Clinical data of LN and SLE patients
Clinical Details LN (n=104) SLE (n=112)
Men 11 (12%) 17 (15%)
Age, yr 34 (14–77) 47 (16–79)
Age at SLE onset, yr 26 (12–77) 37 (7–79)
Disease duration, yr 3 (0.1–24) 7 (0–34)
Serum creatinine, mg/dl 0.9 (0.3–6.4) 0.7 (0.5–1.7)
C3, mg/dl 63 (24–147) 87 (42–154)
Anti-DNA ratio 2.9 (0–26.7) 0.8 (0–11.8)
Anti-C1q, units/ml 166 (10–600) 21 (10–257)
Proteinuria, g/d 2.5 (0.1–20) 0.1 (0–0.3)
Therapy
None 19 (20%) 30 (27%)
Steroids only 39 (42%) 20 (18%)
Multiple therapies 35 (38%) 62 (55%)
LN class
Proliferative (III and IV) 52 (56%)
Membranous (V) 11 (12%)
Mixed 30 (32%)
Datawere collected from216 SLE patients at the time of serum collection and
presented asmedians (ranges); 104 patients had overt LN, and in these cases,
serum collection coincided with the time of renal biopsy. Anti-DNA anti-
bodies were detected by different assays; to unify and analyze data, the anti-
DNA ratio was conceived (Concise Methods). Brieﬂy, an anti-DNA ratio of
one indicates the lowest positive value of each method. Values smaller than
one indicate a negative test. Data about anti-C1q antibodies were available
for only 62 subjects in the non-nephritis group.
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here that a-enolase is recognized by nephritogenic mAbs de-
rived from lupus-prone MRL-lpr/lpr mice12 (clone H147)
that produce renal lesions reminiscent of human LN in
mice. Data in other animal models are weaker because of
the difﬁculty to develop unbiased controls (i.e., antibodies
anti-DNA IgM). Overall, data obtained in BALB/c mice sug-
gested, however, that anti–a-enolase antibodies produce dif-
fuse renal proliferation, highly reminiscent of LN, in only a
percentage of mice. Once again, the limited nephrotoxic po-
tential of anti–a-enolase antibodies in mice is in agreement
with the ﬁnding reported above in human LN showing 50%
positivity of anti–a-enolase antibodies in renal biopsies.
Overall, these data implicate a multicomposition of renal
autoantibodies in LN with a signiﬁcant presence of anti–
a-enolase and anti-annexin AI antibodies. This concept
has been proposed over the years21–24,27 and is strengthened
here by the ﬁnding of a panel of autoantibodies versus en-
dogenous and implanted antigens, such as anti-DNA, anti-
histones, and anti-C1q. It is of interest that positivity for a
single antibody did not exceed 50% of biopsies (see heat map
analysis) for any case, implying a potential multiorigin of
renal lesions. Conﬁrmatory data and new results should
constitute a sound start to approach pathogenesis of
LN.17–20,45 It seems, in particular, that the key aspect is re-
lated to an implication of anti-dsDNA/histone antibodies
as a starter of LN, because these antibodies could not be
detected in a few biopsies. Our results, excluding an inter-
action of a-enolase with anti-dsDNA antibodies, suggest
that other mechanisms and in vivo studies
in the near future may modify the prevail-
ing view of anti-dsDNA as a main player
in LN.
A ﬁnal point of interest is to deﬁne
whether and how the present ﬁndings
would modify the clinical approach to
SLE patients. Indeed, treating LN is a
possible task given that this condition is
rapidly recognized and possibly, antici-
pated. A number of tests have been already
been proposed as surrogate biomarkers of
disease activity inLN.46The list includes anti-
dsDNA, antihistones,47–52 and antibodies
versus endogenous antigens, such as anti-
actinin.10,13,53,54 Actually, deﬁnition of spe-
ciﬁc renal and serum levels of the above
antibodies are inprogress andwill be reported
very soon (G.M. Ghiggeri, unpublished
data). To know the renal isotypes of these
implanted components, it is crucial to look
at the serum levels. Until deﬁnite data are
available, it is difﬁcult to conclude about
sensitivity and correlation among different
components, in which anti–a-enolase and
anti-annexin AI IgG2 should be included in
the list of candidates.
In conclusion, we describe here the presence of several
speciﬁc antibodies versus endogenous glomerular antigens in
glomeruli and sera of a relevant proportionof patientswith LN.
Anti–a-enolase and anti-annexin AI IgG2 seem to be the prev-
alent autoantibody components in glomeruli in vivo. Anti–
a-enolase IgG2 seems to also be implicated in experimental
LN. Amultiantibody panel should be developed as a surrogate
biomarker of LN.
CONCISE METHODS
Patients
Overall, 216 SLE patients were included in the study (Table 2), and
their sera were used for studies on circulating autoantibodies; 103
patients with LN were recruited when they underwent a renal biopsy
for diagnostic purposes. Sera were obtained from all patients at the
time of diagnosis and after months of therapy (T6 and T12) from a
signiﬁcant portion of patients (63 and 68 patients, respectively, after 6
and 12 months). All patients had a diagnosis of LN based on typical
renal lesions. Fresh frozen renal samples were available for 20 patients
and used for the proteomic approach (Table 1). For histologic eval-
uation of kidney disease, Dubosq–Bresil solution-ﬁxed tissues were
embedded in parafﬁn, sectioned, and stained with hematoxylin/eosin,
Masson’s trichrome, silver methenamine, and periodic–acid Schiff.
Routine immunoﬂuorescence studies on frozen sections were per-
formed using anti-human IgG, IgA, IgM, C1q, C3, and ﬁbrinogen an-
tibody.
Table 5. Serum levels of anti–a-enolase and anti-annexin AI IgG2 in LN and SLE
patients and different cohorts of patients who were enrolled in the study
compared with other cohorts presenting primary GN or rheumatoid arthritis
Pathology Group Number Median (mg/L)
Interquartile
Range
Probability
Versus LN
Anti–a-enolase IgG2
LN T0 104 45.37 73.36
T6 74 41.95 52.52 0.09
T12 52 22.21 31.45 0.002
SLE 112 17.44 32.13 ,0.001
RA 50 3.67 8.42 ,0.001
IgAN 60 1.21 10.71 ,0.001
MN 186 6.25 2.16 ,0.001
FSGS 32 1.51 3.54 ,0.001
Controls 135 5.24 9.09 (95°=15.62) ,0.001
Anti-annexin AI IgG2
LN T0 104 4.077 4.250
T6 74 4.394 4.448
T12 52 2.633 2.251 ,0.001
SLE 112 3.422 2.549 0.01
RA 50 2.075 0.904 ,0.001
IgA 60 1.342 1.270 ,0.001
MN 184 1.416 0.944 ,0.001
FSGS 32 1.105 0.086 ,0.001
Controls 116 1.320 0.616 (95°=2.686) ,0.001
Results are given as milligrams per liter. Non-parametric Wilcoxon test for unpaired sample was used
for comparison in different patient cohorts. Results are given as medians and interquartile ranges. RA,
rheumatoid arthritis; IgAN, GN with mesangial IgA deposits; MN, membranous nephropathy.
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Normal Kidneys
Noncarcinomatous portions of kidneys removed for renal cancerwere
obtained from four patients and processed as negative tissue controls
with laser capture.
Other Diseases
Serum was obtained from 50 patients with rheumatoid arthritis and
278 patients with isolated nephritis (186 patients with membranous
nephropathy, 32 patients with FSGS, and 60 patients with IgA
nephritis).Onehundred thirty-ﬁve sera fromnormal peoplewere also
obtained and analyzed.
Ethical Committee
Permission for the study was given on June 10, 2010, by the
Ethical Committee of San Carlo Borromeo Hospital in Milan,
Italy. Informed consent to the study was obtained from all
participants.
Antibodies
Antibody sources are reported as Supplemental Material.
Laser Capture Microdissection and Elution of
Antibodies from Renal Biopsy Tissue
Laser capture microdissection and elution of antibodies were done as
already described29,31; details are given in Supplemental Material.
Two-Dimensional Electrophoresis
Two-dimensional electrophoresis of podocyte extracts (a gift from
M.A. Saleem) was performed in soft gels as described.55 A detailed
description is given in Supplemental Material.
Monodimensional Electrophoresis
Gradient PAGE was done according to the work by Laemmli.56
Gel/Membrane Staining and Image Analysis
After separation in SDS-PAGE gels, proteins were visualized by a double
staining procedure. The methyltrichloroacetate negative staining was
followed by the blue silver colloidal Coomassie57 staining for pre-
parative MS analysis. Images of stained gels were digitized using a
GS800 photometer, and Western blots were acquired using a Versa
DOC 400. All images were analyzed with PD Quest software (Bio-Rad,
Hercules, CA).
Western Blot
Western blotwith glomerular eluates and serawas donewith podocyte
cell linewhole extracts separated by eithermono- or two-dimensional
electrophoresis. Equipment and technique of analysis are described in
Supplemental Material.
Tryptic Digestion and Protein Identiﬁcation by MALDI-
MS and LC-MS
For the identiﬁcation of proteins from two-dimensional electropho-
resis, we used MALDI-MS and LC-MS as described in Supplemental
Material. For MALDI-MS, we used a Voyager-DE PRO mass spec-
trometer (Applied Biosystems, Framingham, MA). For LC-MS, we
used an Orbitrap mass spectrometer (Thermo Fisher Scientiﬁc,
San Jose, CA) coupled to anHPLC Surveyor (Thermo Fisher Scientiﬁc)
and equippedwith a Jupiter C18 columnof 25031mm(Phenomenex).
Details of the analysis procedure are given in Supplemental
Material.
Figure 6. Molecular features of anti–a-enolase antibody. (A–C) Anti–
a-enolase IgG2 interacts with speciﬁc epitope protein. Character-
ization of a-enolase epitopes targets of anti–a-enolase IgG2 and
IgG4; CNBr digests of anti–a-enolase were prepared as described in
Concise Methods and then immunoblotted with IgG2 and IgG4
eluted from glomeruli and serum of patients with LN and MN, re-
spectively. Arrows indicate two different peptides that are recognized
by IgG2 (1.349 kD; ILPVGAANFREAM) and IgG4 (6.822 kD;
DGTENKSKFGANAILGVSLAVCKAGAVEKGVPLYRHIADLAGNSEVIL-
PVPAFNVINGGSHAGNKLAM); the second peptide contains a site
for acetylation. The two epitopes above recognized by IgG2 and
IgG4 have been localized in different regions of a-enolase. (D–F)
Human anti-DNA IgG does not cross-react with a-enolase. Anti-
dsDNA antibodies were puriﬁed from sera of LN patients by afﬁnity
chromatography; (D) they recognized several histones (only H1 and
H2b were negative atWestern blot) but (F) did not recognize a-enolase.
Dot blot analysis was done by increasing the amount of ﬁxed a-enolase
up to 15 mg without showing any interaction. (E) The same histones
separated by monodimensional electrophoresis were recognized by
glomerular eluates. With the same dot blot assay, anti–a-enolase anti-
bodies recognized the antigen at low concentration (5 mg).
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Classic Immunoﬂuorescence and Colocalization
Renal biopsy specimens were embedded in optimal cutting temper-
ature (Tissue Tek; Miles Inc., Elkhart, IN) and stored in liquid
nitrogen. Three-micrometer sections were cut by a cryostat (Leica
CM1850; Leica Mycrosystems) and placed on poly-L-lysine–coated
glass slides for indirect immunostaining. Details of staining are given
in Supplemental Material.
Characterization of Autoantibody Isotype and Levels in
Single Glomerular Eluates and Serum
Autoantibody isotype characterization and single biopsy levels were
evaluated with dot blot using a Bio-Dot apparatus (Bio-Rad) as
described in SupplementalMaterial. The same technique was used for
the determination of anti–a-enolase serum levels; an ELISAwas also
developed to conﬁrm results.
Anti–a-Enolase ELISA
A method for determining serum a-enolase levels in serum was de-
veloped. Main characteristics and steps of the procedure are illus-
trated in Supplemental Material.
Anti-Annexin AI ELISA
For anti-annexin AI, we used a self-made ELISA (Supplemental Material).
CNBr Digestion of a-Enolase and Analysis of
Fragmentation Binding
For digestionwithCNBr,a-enolase (10mg)methods are illustrated in
Supplemental Material.
Isolation of Serum Anti-DNA Antibodies
Isolation of anti-dsDNAantibodies from sera of patients with SLEwas
done according to the work by Chan and colleagues.32 Details are
given in Supplemental Material.
Nepritogenic Monoclonal Anti-DNA IgG2 Clone (H147)
Derived from Lupus-Prone MRL-lpr/lpr Mice
Nepritogenicmonoclonal anti-DNA IgG2 clone (H147) derived from
lupus-proneMRL-lpr/lprmicewas furnished byM.M. Techniques for
developing hybridomas have been reported in detail in previous
works.17,45 mAbs were puriﬁed from hybridoma supernatants by af-
ﬁnity chromatographys.18
Anti–a-Enolase IgG in BALB/c Mice
Twenty-two BALB/c and six SCID mice were injected intraperitone-
ally with 13106 hybridoma cells producing anti–a-enolase mAbs;
proteinuria and renal pathology were tested at weekly intervals (Sup-
plemental Material).
Statistical Analyses
Serum levels of antibodies were expressed asmedian and interquartile
range. A nonparametric Wilcoxon test for unpaired samples was used
for comparison of anti–a-enolase IgG2 or anti-annexin AI IgG2
serum titer in different patient cohorts, whereas a nonparametric
Wilcoxon test for paired samples was used for comparison of anti–
a-enolase IgG2 or anti-annexin AI IgG2 LN serum titer at different
times. Statistical analysis was performed using the R software.
Figure 7. Experimental lupus nephritis. (A) mAbs from nephritogenic hybridomas recognize a-enolase. Nepritogenic monoclonal anti-
DNA IgG2 clone (H147) derived from lupus-prone MRL-lpr/lpr mice was furnished by M.M. On dot blot using dilutions of the original
hybridoma, a speciﬁc reaction with a-enolase was found. Techniques for developing hybridomas have been reported in detail in
previous works.17,45 (B–F) Anti–a-enolase IgG infusion produced proliferative renal lesions in BALB/c and SCID mice. Twenty-two
BALB/c mice were injected intraperitoneally with 13106 hybridoma cells producing anti–a-enolase mAbs58; hybridoma cells producing
IgM anti-DNA antibodies were injected into three BALB/c mice as controls. After 10 days, six mice developed proteinuria (100–300 mg%).
(B and C) Controls and other mice had proteinuria less than 1 mg/ml. Gross pathology is reported in D, and it shows hematoxylin/eosin
(HE; 3100 and 3200) and periodic–acid Schiff (PAS) staining. In E, immunostaining for nonmuscle myosin (aSMA) is shown; in mice
infused with anti–a-enolase antibodies, mesangial deposits of aSMA were seen in glomeruli and small vessels (where aSMA is
physiologic), whereas no mesangial staining could be seen in mice injected with anti-DNA IgM (3200). (F) Four of six SCID mice
similarly injected with the same hybridomas developed proliferative GN with crescents and tubulointerstitial lesions.
J Am Soc Nephrol 25: 2483–2498, 2014 In Vivo Lupus Autoantibodies 2495
www.jasn.org BASIC RESEARCH
Differences were considered statistically signiﬁcant at two-tailed
P values ,0.05.
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anti–a-enolase IgG2 antibodies as surrogate biomarkers of lupus
nephritis is pending.
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